There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients.
However, the need for additional postmarketing studies is required by the FDA.
Some “Canagliflozin” Factoids:
- Canagliflozin does not rely on patient’s insulin levels to succeed.
- Canagliflozin is a unique inhibitor of sodium glucose co-transporter 2, as well as a potential treatment for type 2 diabetes.
- Results from five Phase lll clinical trials, which were presented at the 72nd American Diabetes Association Annual Scientific Sessions on June 9, 2012.
- Results in favor of Canagliflozin were positive, showing that a once daily 300 mg dose of this medication provided significantly greater reductions in A1C levels relative to comparators.
- In January 2013 an FDA Advisory Committee recommended approval of Canagliflozin for type 2 diabetes in adults based on efficacy & safety results from the comprehensive clinical development program
- Canagliflozin CAS# 842133-18-0 is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney
- Canagliflozin will be marketed under the brand name INVOKANA™ by J&J
LGM Pharma provides Canagliflozin CAS# 842133-18-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.